How Best to Make the Switch to Clozapine

How to interpret antipsychotic drug levels in schizophrenia: when labs mislead, when levels help adherence and toxicity checks, and why serial monitoring matters.

Therapeutic drug monitoring takes guesswork out of antipsychotic care—spotting nonadherence, guiding dose targets, and defining response thresholds and the “point of futility” in schizophrenia.

Once-monthly subcutaneous olanzapine LAI requires no loading doses, oral supplementation, or post-injection monitoring, based on phase 3 SOLARIS data.

Once-monthly subcutaneous olanzapine TEV-749 shows sustained stabilization and remission in schizophrenia, supports direct switching, and avoids post-injection monitoring.

Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.

Despite previous failure of PDE10A inhibitor drugs to demonstrate antipsychotic effects in clinical trials, a new "improved" iteration has met phase 2 trial endpoints.

FDA approves monthly subcutaneous olanzapine LAI Weltruza, expanding schizophrenia treatment options and renewing debate on making long-acting injectables routine.

How past “untreatable” labels mislead psychiatry—and why measurement-informed care and difficult-to-treat depression replace today’s treatment-resistant mindset.